| Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
|
Immunotherapy |
Aplastic Anemia |
| Granulocyte transfusions in severe aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations |
|
Journal of Blood Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
|
Haematologica |
Aplastic Anemia |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia |
|
International Journal of Hematology |
Aplastic Anemia |
| Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
